Role of Diet on the Microbiome of the Digestive System
Launched by M.D. ANDERSON CANCER CENTER · Dec 8, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how different diets affect the bacteria and microorganisms in our digestive system, which is called the microbiome. The researchers are particularly interested in understanding if these dietary influences might play a role in the development of colorectal cancer, a type of cancer that affects the colon and rectum. They are currently looking for participants to help with this study.
To be eligible, participants should be 45 years or older and must be undergoing a routine screening colonoscopy. There are two groups in the study: one group follows a strict vegetarian diet, while the other group eats a mixed diet that includes meat (omnivorous). It’s important that participants do not smoke and are willing to complete some dietary assessments and provide samples of their stool, blood, and colon tissue. If you qualify and choose to participate, you’ll help researchers learn more about the connection between diet and colorectal cancer, which could lead to better prevention strategies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • GROUP I: Patients presenting for a screening colonoscopy
- • GROUP I: Age of 45 and above
- • GROUP I: Strict vegetarian diet, determined by using diet history questionnaire 3.0 National Institutes of Health (NIH)
- • GROUP I: Non smoker
- • GROUP I: Ability to understand and willingness to sign an informed consent form, complete web based dietary assessment and provide stool, colonic mucosa and blood samples
- • GROUP II: Patients presenting for a screening colonoscopy
- • GROUP II: Age of 45 and above
- • GROUP II: Omnivorous diet
- • GROUP II: Non smoker
- • GROUP II: Ability to understand and willingness to sign an informed consent form, complete web based dietary assessment and provide stool, colonic mucosa and blood sample
- Exclusion Criteria:
- • • Current smokers (nicotine abuse only)
- • Positive family history of colon cancer or colon cancer related syndromes
- • Recent use of antibiotics in 1 month
- • History of inflammatory bowel disease, and/or radiation enteritis or colitis
- • Pregnant and breastfeeding women
- • Women of child-bearing potential who have positive urine or serum pregnancy test
- • Heavy drinker (defined as more than 14 drinks per week)
- • Currently using anti-flatulence medications, probiotics and/or fiber supplements
- • Major dietary restrictions and/or following a special diet
- • Patient with positive fecal test/symptoms
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Houston, Texas, United States
Patients applied
Trial Officials
Anusha Thomas, MD
Principal Investigator
MD Anderson Cancer Center, Houston, Texas
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials